Sponsor | Number of Studies |
---|---|
GlaxoSmithKline | 3486 |
Assiut University | 3455 |
National Cancer Institute (NCI) | 3427 |
Cairo University | 3128 |
Pfizer | 3063 |
AstraZeneca | 3063 |
Assistance Publique - Hôpitaux de Paris | 2998 |
Mayo Clinic | 2808 |
M.D. Anderson Cancer Center | 2725 |
Novartis Pharmaceuticals | 2404 |
Cracking the code
In the realm of clinical trials, a select few sponsors stand out as the driving forces behind groundbreaking research. GlaxoSmithKline leads the pack with an impressive 3486 studies, followed closely by Assiut University and the National Cancer Institute (NCI). These top sponsors have collectively contributed to over 30% of the total studies conducted. The diversity in sponsor types, from pharmaceutical giants like Pfizer and Novartis to esteemed institutions like Mayo Clinic and M.D. Anderson Cancer Center, showcases the collaborative nature of clinical research. While the data highlights the dominance of a few key players, it also underscores the need for greater representation and participation from a wider range of sponsors.
Trend in Clinical Trials Initiated in the US Over the Last Three Years
Trend of Clinical Trials Over the Last 10 Years
Comparison of Clinical Trials in Canada vs United States Over the Years
Trend in Clinical Trials Initiated in Singapore Over the Last Three Years
Total Enrollment in Phase I, II, and III for the Year 2024
Trend in Number of Phase III Trials Initiated from 2021 to 2023
Distribution of Study Phases
Trends in Study Completion Over Time
Count of Oncology Trials Starting in the Next 3 Months
HbA1c Improvement Observed with BASAGLAR in Type 2 Diabetes Patients
Trend in Clinical Trials Initiated in the US vs EU in the Last Three Years
Top Pharmaceutical Companies by Number of Trials Published in the Last 5 Years